Treating ophthalmic fibrosis using interferon-.alpha.

Details Treating ophthalmic fibrosis using interferon-.alpha. Treating ophthalmic fibrosis using interferon-.alpha.

1996-10-04

1999-01-26

Sayala, Chhaya D.

Drug, bio-affecting and body treating compositions

Lymphokine

Interferon

530351, A61K 3821

Patent

active

058635300

ABSTRACT:
The present invention relates to the use of topical interferon-.alpha. for the treatment of various forms of fibrosis in and around the eye arising from various ophthalmic diseases and procedures. Specifically the invention relates to alleviation of corneal scarring after laser photoablative refractive keratectomy (PRK). It aslo relates to the alleviation of posterior (lens) capsular opacification after extracapsular cataract surgery with lens implant; the alleviation of wound scarring following glaucoma filtration surgery. Interferon-.alpha. may also be used to coat the lens implant prior to or during implantation. It may also possibly be injected into the eye during eye surgery for inhibiting posterior capsule opacification after cataract surgery and in addition may be injected into the vitreous body to prevent retinal fibrosis and proliferative vitreo-retinopathy, and injected subconjunctivally to inhibit fibrosis and scarring following glaucoma filtration surgery,.

REFERENCES:
patent: 4507281 (1985-03-01), Asculai et al.
patent: 4857311 (1989-08-01), Domb et al.
patent: 4863457 (1989-09-01), Lee
Johnson-Wint, Ana. N.Y. Acad. Sci., vol. 548, pp. 167-173, 1988.
Gillies et al., Araefe's Archive for Clin & Exptal Ophthalmol., vol. 231, pp.118-121, 1993.
Duncan et al., J. Clin. Invest., vol. 79, pp. 1318-1324, 1987.
Berman et al., J. Am. Acad. Dermatol., vol. 21, pp. 694-702, 1989.
Duncan et al., Arch. Dermatol. Res., vol. 281, pp. 11-18, 1989.
Kahari et al., Biochim. et Biophysica Acta, vol. 968, pp. 45-50, 1988.
Dharma et al., Ophthalamic Surg., vol. 18(1), pp. 51-54, 1987.
Vegh et al., Ophthalamic Surg., vol. 17(2), pp. 103-105, 1987.
Jimenez et al., J. Clin. Invest., vol. 74, pp. 1112-1116, 1984.
Siebert et al., Plastic & Reconstr. Surg., vol. 85(4), pp. 495-502, 1990.
Garty DS, Kerr Muir MG, Marshall J. Excimer laser photorefractive keratectomy. 18 month follow up. Ophthalmology 1992;1209-1219.
Sher NA, Barak M, Daya S, De Marchi J, Tucci A, Hardten DR et al. Excimer laser photorefractive keratectomy in high myopia. A multicenter study. Arch Ophthalmol 1992; 110:935-943.
Gressel MG, Parrish RK II and Folberg R: 5-fluorouracil and glaucoma filtering surgery I. An animal model. Ophthalmology 1984; 91:378-83.
McDonald HR, Schatz II, Johnson RN. Introduction to epiretinal membranes. In Retina, Ryan SJ, ed., 2nd edition, St. Louis 1994, Mosby, pp. 1819-1825.
Blumenkraz MS, Claflin A and Hajek A: Selection of therapeutic agents for intraocular proliferative disease; cell cultire evaluation. Arch Ophthalmol 1984; 102:598-604.
Jimenez SA, Freundlich B and Rosenblom J. Selective inhibition of human diploid fibroblast collagen synthesis by interferons. J Clin Invest 1984; 74:1112-6.
Duncan MR and Berman B. Persistence of a reduced collagen-producing phenotype is cultured scleroderma fibroblasts after short-term exposure to interferons. J Clin Invest 1987; 79:1318-24.
Low SQ, Kitada S, Lee DA. Interferon-.gamma. inhibits collagen synthesis by human Tenon's capsule fibroblasts in vitro Invest Ophthalmol Vis Sci 1991; 32:2964-9.

Affiliated with

Also associated with

Rating

Treating ophthalmic fibrosis using interferon-.alpha. does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Treating ophthalmic fibrosis using interferon-.alpha., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treating ophthalmic fibrosis using interferon-.alpha. will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1447987